The PSMAt peptide, which targets the prostate-specific membrane antigen (PSMA), has had clinical impact as a vector for delivering radionuclides to prostate cancer for diagnostic imaging and systemic peptide receptor radionuclide therapy (PRRT). Here, FOLH1 is linked to prostate cancer.